BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Up 2.4% - Should You Buy?

Key Points

• BioRestorative Therapies stock increased by 2.4% to $1.70, but trading volume significantly dropped to 34,997 shares, compared to the average of over 62 million shares.
• The company has a market cap of $2.66 billion and a negative P/E ratio of -1.51, suggesting potential financial challenges.
• BioRestorative focuses on developing therapeutic products using adult stem cells, particularly for disc/spine diseases and metabolic disorders, including their lead candidate BRTX-100.

Shares of BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ - Get Free Report) were up 2.4% during mid-day trading on Thursday . The company traded as high as $1.70 and last traded at $1.70. Approximately 34,997 shares changed hands during trading, a decline of 100% from the average daily volume of 62,169,492 shares. The stock had previously closed at $1.66.

BioRestorative Therapies Trading Down 1.5%

The stock has a 50-day simple moving average of $1.67 and a 200-day simple moving average of $1.80. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -1.51 and a beta of 102.36.

About BioRestorative Therapies

BioRestorative Therapies, Inc develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders.